Floatz logo

Polyiclc

Merkel Cell Carcinoma

University of Southern CaliforniaPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Merkel Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 2/3B
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Fludarabine
Sotio Biotech Inc.
Phase 2B

View all 50 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →